DNA synthesis or function inhibition

DNA synthesis or function inhibition refers to the pharmacological intervention targeting the molecular machinery responsible for replicating and maintaining cellular DNA. The main enzymatic targets include DNA polymerases (which synthesize new DNA strands), topoisomerases (which resolve DNA supercoiling and knots), and DNA ligases (which join DNA fragments during replication and repair). Therapeutic inhibition disrupts cellular proliferation and survival, particularly in rapidly dividing cells such as cancer cells or infected cells. Drugs targeting these proteins include nucleoside analogs, DNA-damaging agents, topoisomerase inhibitors, antimetabolites, and agents interfering with nucleotide metabolism. While these strategies are highly effective against cancers and some infections, their lack of selectivity can cause significant toxicity, risk of secondary cancers, and drug resistance. Advances continue in developing more selective inhibitors and identifying biomarkers to improve safety and efficacy[1][2][3][4][5][6][7].

Other names

DNA replication inhibitionDNA repair inhibitionDNA polymerase inhibitionTopoisomerase inhibitionDNA ligase inhibition

Inhibition of DNA polymerase activity (prevents nucleotide addition and strand elongation) - DNA damage induction (causing breaks or crosslinks that block replication and/or repair) - Inhibition of nucleotide metabolism (reducing dNTP pools essential for synthesis) - Topoisomerase inhibition (prevents DNA unwinding or re-ligation during synthesis and repair) - DNA ligase inhibition (blocks the joining of DNA fragments in replication or repair)